Eli Lilly rises 2.8% premarket after China approves weight-loss pill orforglipron
Investing.com · · AI-summarised by FinFlash
Eli Lilly shares gained 2.8% in US premarket trading after China's drug regulator approved its oral weight-loss drug orforglipron, a potential edge over rival Novo Nordisk in the Chinese market. Nvidia's slide, by contrast, dragged chip names such as Micron and SK Hynix lower. The move came as US index futures were mixed, with Nasdaq 100 futures down 0.64% at 05:32 ET on Nvidia leadership turmoil, while Dow futures rose 0.12% and S&P 500 futures fell 0.31%.
So What?
Positive for Lilly's international GLP-1 growth story and a competitive negative for Novo Nordisk in China; healthcare may act as a defensive haven while chip stocks wobble.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.